GCAD, which was established in 2016, coordinates the integration and meta-analysis of Alzheimer’s disease genetic data, including data generated by ADSP. Key activities include:
- Assembling and harmonizing whole-genome sequencing (WGS) and whole-exome sequencing (WES) data.
- Designing and implementing quality control (QC) pipelines for WGS and WES data.
- Building ADRD-specific reference panels from GCAD data for imputation of genome-wide genotypes
- Calling structural variants from sequencing data.
- Supporting the ADSP analysis teams, including functional genomics, cognitive systems, and phenotype harmonization efforts.
- Facilitating analysis of GCAD genetic and functional data collections.
- Identifying candidate therapeutic targets by combining and reviewing analysis results generated by GCAD and other ADSP and non-ADSP projects.
- Broadly disseminating all results and derivative data.
NIH Project Number
Website(s)
Associated Groups
The GCAD-QC Working Group meeting is used to discuss genomic data production, pipeline development, pipeline testing and updates, QC, and release progress. Reports and updates are provided by GCAD and NIAGADS. The meetings provide a forum for ADSP members to provide input and ask questions.
Associated Grants (Current)
| Project # (Links to RePORTER) | Grant Name | Investigators | FOA(s) | Project Start Date | Project End Date |
|---|---|---|---|---|---|
| U54AG052427 | Genome Center for Alzheimer’s Disease (GCAD) | Contact PI:
|
PAR-19-288, RFA-AG-16-001 |
None